Victory Completes Mag Survey of Its Tahlo Lake Property in the Babine Copper-GOLD Poryphyry District
NETRAMARK,
THE
FIRST
PUBLIC
AI
COMPANY
TO
LAUNCH
CLINICAL
TRIAL
DE-RISKING
TECHNOLOGY
THAT
INTEGRATES
CHATGPT
TORONTO,
ON,
May
16,
2023
–
NetraMark
Holdings
Inc
.
(the
“Company”
or
“NetraMark”)
(CSE:
AIAI)
(Frankfurt:
8TV)
(OTC:
AINMF)
announces
the
release
of
NetraGPT.
Through
newly
developed
algorithms,
NetraGPT
builds
upon
the
powerful
hypotheses
generated
from
the
Company’s
proprietary
Good
Clinical
Practice
(GCP)
validated
AI/
ML
system,
NetraAI.
The
power
of
the
NetraAI
system
lies
in
its
ability
to
learn
about
special
combinations
of
variables
that
define
patient
subpopulations
in
relation
to
drug
or
placebo
response
and
adverse
effects,
all
of
which
are
important
considerations
for
clinical
trials.
NetraGPT
now
revolutionizes
the
power
of
NetraAI
whereby
the
NetraAI
output
is
fed
into
generative
pre-trained
(GPT)
models
utilizing
Large
Language
Model
(LLM)
APIs.
Currently,
LLMs
are
being
trained
with
a
massive
volume
of
data,
with
ChatGPT4
being
trained
on
approximately
300
billion
words
of
data,
including
medical
literature.
This
innovation
places
NetraMark
in
a
unique
position
to
not
only
build
upon
the
hypothesis
and
subpopulation
definitions
derived
from
NetraAI
but
to
now
also
potentially
discover
further
insights
that
leverage
the
power
of
LLMs
and
deliver
the
output
reports
in
minutes
vs.
weeks.
This
creates
an
unprecedented
opportunity
for
NetraMark
to
seamlessly
integrate
output
from
NetraAI
and
quickly
convey
potent
insights
about
patient
populations
to
our
clientele
with
heightened
efficiency
and
explainability.
NetraGPT
NetraGPT
ingests
information
about
specific
clinical
trial
patient
subpopulations
discovered
by
NetraAI.
More
specifically,
this
involves
feeding
the
collection
of
variables,
biological
or
otherwise,
that
are
statistically
significant
for
the
discovered
subpopulations
of
interest,
based
on
the
dependent
variable,
e.g.,
drug
response,
placebo
response,
placebo
non-response,
adverse
event,
etc.
The
resulting
output
of
the
NetraGPT
module
is
a
detailed
human-readable
report
that
leverages
the
power
of
LLMs
and
the
massive
corpus
of
medical
literature
to
provide:
●
Output
reports
that
begin
to
assemble
in
seconds
and
conclude
within
minutes
●
Improved
explainability
of
the
influential
variables
underlying
discovered
subpopulations
●
Additional
insights
delineating
interconnections
among
variables,
the
response,
and
the
disease
state
●
References
sourced
from
relevant
and
contemporary
literature
Importantly,
the
process
is
transparent
about
the
variables
driving
the
specific
patient
subpopulations
that
can
be
clearly
identified
and
validated
through
statistical
inspection.
This
level
of
transparency
is
critical
for
sponsors,
particularly
when
working
with
LLMs,
as
it
allows
human
experts
and
trialists
to
audit
parts
of
the
hypothesis-generation
artificial
intelligence
(AI)
process
and
the
LLM-generated
report,
to
ensure
the
veracity
of
the
generated
insights
and
recommendations.
“NetraGPT
is
a
critical
and
differentiated
offering
that
places
NetraMark
at
the
forefront
of
AI
innovation
for
clinical
trial
de-risking
in
the
Pharmaceutical
Industry.
This
will
allow
us
to
deliver
critical
insights
to
our
clients
very
quickly
and
allow
them
to
proceed
with
critical
trial
enrichment
decisions
faster
and
with
more
clarity.
This
is
an
exciting
time
for
the
Company,
as
we
share
NetraGPT
with
key
decision
makers
in
the
industry,”
said
Josh
Spiegel,
President
NetraMark.
“LLMs,
like
ChatGPT,
have
recently
achieved
a
level
of
sophistication
that
is
enabling
practical
innovation
for
a
variety
of
use
cases.
NetraAI
is
built
to
explain
what
it
finds
and
this
property
makes
our
technology
an
optimal
partner
for
ChatGPT.
Through
new
algorithm
development
at
NetraMark,
this
fusion
between
NetraAI
and
ChatGPT
provides
a
cutting
edge
insight
engine
for
clinical
trial
patient
populations
that
can
be
delivered
quickly
and
with
clarity,”
said
Dr.
Joseph
Geraci,
CTO
/
CSO
NetraMark.
Additional
information,
including
sample
outputs
from
NetraGPT,
can
be
found
here:
NetraGPT
White
Paper
About
NetraMark
NetraMark
is
a
company
focused
on
being
a
leader
in
the
development
of
Artificial
Intelligence
(AI)
/
Machine
Learning
(ML)
solutions
targeted
at
the
Pharmaceutical
industry.
Its
product
offering
uses
a
novel
topology-based
algorithm
that
has
the
ability
to
parse
patient
data
sets
into
subsets
of
people
that
are
strongly
related
according
to
several
variables
simultaneously.
This
allows
NetraMark
to
use
a
variety
of
ML
methods,
depending
on
the
character
and
size
of
the
data,
to
transform
the
data
into
powerfully
intelligent
data
that
activates
traditional
AI
/
ML
methods.
The
result
is
that
NetraMark
can
work
with
much
smaller
datasets
and
accurately
segment
diseases
into
different
types,
as
well
as
accurately
classify
patients
for
sensitivity
to
drugs
and
/
or
efficacy
of
treatment.
For
further
details
on
the
Company
please
see
the
Company’s
publicly
available
documents
filed
on
the
System
for
Electronic
Document
Analysis
and
Retrieval
(SEDAR).
Company
contact
information:
Swapan
Kakumanu
-
CFO
|
|
403-681-2549
Forward-Looking
Statements
This
press
release
contains
"forward-looking
information"
within
the
meaning
of
applicable
Canadian
securities
legislation
including
statements
regarding
the
power
of
NetraGPT
to
generate
hypothesis
and
reports
more
efficiently
with
improved
explainability
of
the
influential
variables
underlying
discovered
subpopulations,
additional
insights
into
interconnections
among
variables
and
the
response
and
the
disease
state
and
scientific
or
medical
references,
the
uniqueness
of
NetraMark’s
position
to
integrate
and
use
this
technology
and
the
ability
to
deliver
critical
insights
to
our
clients
quickly
and
allow
them
to
proceed
with
critical
trial
enrichment
decisions
faster
and
with
more
clarity
which
are
based
upon
NetraMark’s
current
internal
expectations,
estimates,
projections,
assumptions
and
beliefs,
and
views
of
future
events.
Forward-looking
information
can
be
identified
by
the
use
of
forward-looking
terminology
such
as
"expect",
"likely",
"may",
"will",
"should",
"intend",
"anticipate",
"potential",
"proposed",
"estimate"
and
other
similar
words,
including
negative
and
grammatical
variations
thereof,
or
statements
that
certain
events
or
conditions
"may",
"would"
or
"will"
happen,
or
by
discussions
of
strategy.
Forward-looking
information
includes
estimates,
plans,
expectations,
opinions,
forecasts,
projections,
targets,
guidance,
or
other
statements
that
are
not
statements
of
fact.
The
forward-looking
statements
are
expectations
only
and
are
subject
to
known
and
unknown,
risks,
uncertainties
and
other
important
factors
that
could
cause
actual
results
of
the
Company
or
industry
results
to
differ
materially
from
future
results,
performance
or
achievements.
Any
forward-looking
information
speaks
only
as
of
the
date
on
which
it
is
made,
and,
except
as
required
by
law,
NetraMark
does
not
undertake
any
obligation
to
update
or
revise
any
forward-looking
information,
whether
as
a
result
of
new
information,
future
events,
or
otherwise.
New
factors
emerge
from
time
to
time,
and
it
is
not
possible
for
NetraMark
to
predict
all
such
factors.
When
considering
these
forward-looking
statements,
readers
should
keep
in
mind
the
risk
factors
and
other
cautionary
statements
as
set
out
in
the
materials
we
file
with
applicable
Canadian
securities
regulatory
authorities
on
SEDAR
at
www.sedar.com
including
our
Management’s
Discussion
and
Analysis
for
the
year
ended
September
30,
2022.
These
risk
factors
and
other
factors
could
cause
actual
events
or
results
to
differ
materially
from
those
described
in
any
forward-looking
information.
The
CSE
does
not
accept
responsibility
for
the
adequacy
or
accuracy
of
this
release.